What does del(7q) in96% of cells indicate about disease aggression? Format your response so a patient skimming on...

TL;DR: Del(7q) in 96% of your cells is a serious finding that typically means your MDS is aggressive and likely to worsen without treatment—this is exactly why your doctors are discussing stem cell transplant options with you.

---

KEY POINTS:

• Del(7q) is a high-risk cytogenetic abnormality — it's one of the most concerning chromosomal changes in MDS and strongly predicts disease progression
• 96% involvement means nearly all your bone marrow cells carry this deletion — this indicates widespread disease, not just a small clone
• Del(7q) is associated with shorter survival and higher risk of transformation to acute myeloid leukemia (AML) without treatment
• This finding is a major reason allogeneic hematopoietic stem cell transplant (allo-HSCT) is typically recommended — it's one of the few treatments that can potentially cure MDS with del(7q)
• Your mixed donor chimerism status after transplant is being monitored closely because del(7q) MDS can relapse, and chimerism levels help predict relapse risk

---

NEXT STEP:

Ask your transplant team specifically: "Given my del(7q) in 96% of cells and my current mixed chimerism status, what is the relapse risk, and what interventions (like donor lymphocyte infusion) might be considered if my chimerism decreases?"

---

FULL ANSWER

What Del(7q) Means in Your MDS

Del(7q) means you have a deletion of the long arm (q) of chromosome 7—essentially, a piece of chromosome 7 is missing in your bone marrow cells. When this deletion is found in 96% of your cells, it tells your doctors several critical things about your disease:

1. This Is a High-Risk Cytogenetic Finding

According to NCCN Guidelines for Myelodysplastic Syndromes, del(7q) is classified as a high-risk or very high-risk cytogenetic abnormality depending on the specific context. Your specific deletion—del(7q31) (affecting the 7q31 region)—is particularly concerning because:

• It's associated with monosomy 7-like disease (behaving similarly to loss of the entire chromosome 7)
• Monosomy 7 and del(7q) are among the most aggressive cytogenetic abnormalities in MDS
• These deletions typically indicate poor prognosis without treatment

2. 96% Involvement = Widespread Disease

The fact that 96% of your cells carry this deletion means:

• This is not a small, contained clone — nearly your entire bone marrow population carries the abnormality
• The disease is clonally dominant — the del(7q) clone has taken over your bone marrow
• This level of involvement typically correlates with more rapid disease progression and higher risk of transformation to acute myeloid leukemia (AML)

3. Disease Aggression and Progression Risk

Del(7q) MDS is known for:

• Rapid cytopenia development — your blood counts (red cells, white cells, platelets) typically decline faster than in other MDS subtypes
• High transformation risk to AML — studies show that del(7q) MDS transforms to AML in approximately 40-60% of patients within 2-3 years without treatment
• Shorter overall survival — median survival for untreated del(7q) MDS is typically 1-2 years, compared to 3-5+ years for lower-risk MDS

This directly relates to your question about "How quickly might I expect worsening cytopenias?" — with del(7q) in 96% of cells, worsening is typically expected within months to 1-2 years without intervention.

4. Why Your Doctors Recommended Allo-HSCT

Your del(7q) finding is a major indication for allogeneic hematopoietic stem cell transplant (allo-HSCT) because:

• Allo-HSCT is the only potentially curative treatment for high-risk MDS like yours
• The graft-versus-leukemia (GVL) effect — where donor immune cells attack remaining MDS/leukemia cells — is critical for controlling del(7q) disease
• Without transplant, progression to AML is likely, and AML arising from del(7q) MDS is particularly difficult to treat

This is why your transplant team likely emphasized the importance of proceeding with transplant rather than watching and waiting.

5. Your Current Post-Transplant Status: Mixed Chimerism

Your recent results show mixed donor chimerism ([date removed]), which means:

• Your bone marrow contains both donor cells (from the transplant) and your own remaining cells
• This is being monitored closely because del(7q) MDS can relapse if your own MDS cells re-expand
• Chimerism levels are a key predictor of relapse risk — decreasing donor chimerism may signal impending relapse

Your doctors are likely tracking:

• CD34+ cells (immature blood-forming cells) — to see if MDS blasts are re-emerging
• CD15, CD19, CD3 (mature blood cell markers) — to assess the balance of donor vs. recipient cells in different lineages

6. Prognosis Without Another Allo-HSCT

Regarding your question: "What is my prognosis if I don't have another Allo-HSCT?"

According to NCCN MDS Guidelines and ASCO recommendations:

• If your MDS relapses after your first transplant, a second allo-HSCT (or alternative approaches like donor lymphocyte infusion, hypomethylating agents, or clinical trials) may be considered
• Relapsed del(7q) MDS has a poor prognosis — median survival after relapse is typically 6-12 months without further treatment
• However, outcomes vary significantly based on:
  • Time to relapse (earlier relapse = worse prognosis)
  • Availability of a second transplant or alternative donor
  • Your overall health and ability to tolerate further treatment
  • Response to bridge therapies (like azacitidine or decitabine) while planning next steps

---

Questions to Ask Your Transplant Team

Given your del(7q) in 96% of cells and mixed chimerism status:

1. "What is my current relapse risk based on my chimerism levels and CD34 counts?"
2. "How frequently will you monitor my chimerism, and what chimerism level would trigger intervention?"
3. "If my MDS relapses, what are my options? (e.g., donor lymphocyte infusion, second transplant, clinical trials)"
4. "Are there any clinical trials for relapsed del(7q) MDS that I might be eligible for?"
5. "What symptoms or lab changes should I watch for that might indicate relapse?"

---

Authoritative Sources

This information is based on:

• NCCN Clinical Practice Guidelines for Myelodysplastic Syndromes (most recent version) — which classify del(7q) as high-risk and recommend allo-HSCT
• American Society of Clinical Oncology (ASCO) Guidelines on MDS — which discuss prognosis and treatment of high-risk cytogenetics
• National Cancer Institute (NCI) MDS Information — which provides patient-friendly summaries of cytogenetic risk stratification

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about your specific situation, especially regarding relapse risk and treatment options if your disease recurs.